stockrowAurinia Pharmaceuticals Inc (AUPH) vs NewAmsterdam Pharma Company N.V. (NAMS)
- Aurinia Pharmaceuticals Inc AUPH 16.42 +1.30%
- NewAmsterdam Pharma Company N.V. NAMS 19.02 +0.69%
Aurinia Pharmaceuticals Inc and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and NewAmsterdam Pharma Company N.V. are of similar size ($2.3B and $2.2B). NewAmsterdam Pharma Company N.V. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 21.0% against −26.4%. Aurinia Pharmaceuticals Inc has the higher net margin (97.7% vs −789.9%) and the higher return on invested capital (43.0% vs −13,975.8%). Across the 17 metrics below, Aurinia Pharmaceuticals Inc leads on 14 and NewAmsterdam Pharma Company N.V. on 3.
Valuation
Profitability
| Metric | AUPH | NAMS | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.62% | 100.00% | 68.51% |
| Operating margin | 44.78% | (900.07%) | 0.00% |
| Net margin | 97.68% | (789.94%) | 0.00% |
| Free cash flow margin | 55.02% | (581.64%) | 0.00% |
| Return on equity | 61.42% | (30.16%) | (51.96%) |
| Return on assets | 46.45% | (27.79%) | (46.06%) |
| Return on invested capital | 42.95% | (13,975.75%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack